Recent clinical efforts, such as the SKYSCRAPER-01 trial combining PDL1 blockade with an anti-TIGIT Ab, have failed to lead to improved responses in lung cancer, and there is a need to better understand the mechanisms of immune evasion in order to design rational combination strategies that are more likely to provide clinical benefit. This evidence concerns the gene CD274 and lung cancer.